生物製药 CMO/CRO 市场规模、份额和成长分析（按供应来源、服务类型、产品和地区）：产业预测（2025-2032）

2023年全球生物製药CMO/CRO市场规模估值为324亿美元，从2024年的343.1亿美元成长到2032年的542.8亿美元，在预测期内（2025-2032年）复合年增长率预计将达到5.9% 。

生物製药产业经历了快速成长，目前占全球製药市场的20%以上。这种扩张受到了 COVID-19 大流行以及旨在提高行业生产力和效率的投资增加的显着影响。随着生物製药公司专注于外包资源密集流程，他们对合约业务组织（CMO）和委外研发机构（CRO）的依赖激增，为其服务创造了利润丰厚的需求。最近的合作，例如澳洲政府对山德士在抗生素生产方面的投资，进一步凸显了该行业对创新和全面解决方案的承诺。该领域的併购使奇美生物能够提供全面的生物加工服务，使其成为快速产品开发和市场进入的重要合作伙伴。

目录

介绍

• 分析目的
• 市场范围
• 定义

分析方法

• 资讯采购
• 次要/主要资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 市场概况及展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析

主要市场考虑因素

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场魅力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步

全球生物製药 CMO/CRO 市场规模和复合年增长率：按来源分类（2025-2032）

• 市场概况
• 哺乳动物细胞
• 非哺乳动物细胞

全球生物製药 CMO/CRO 市场规模和复合年增长率：按服务类型划分（2025-2032）

• 市场概况
• 契约製造
  • 製程开发
  • 下游
  • 上游
  • 填充/整理工作
  • 分析/品管研究
  • 包装
• 委託研究
  • 肿瘤学
  • 发炎/免疫学
  • 心臟病学
  • 神经科学
  • 其他的

全球生物製药 CMO/CRO 市场规模和复合年增长率：按产品分类（2025-2032）

• 市场概况
• 生技药品
  • 单株抗体 (MAb)
  • 重组蛋白
  • 疫苗
  • 反义RNAi分子疗法
  • 其他的
• 生物相似药

全球生物製药CMO/CRO市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争格局

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要企业采取的策略
• 近期市场趋势
• 主要企业市场占有率（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• 龙沙集团（瑞士）
• 赛默飞世尔科技（美国）
• 康塔伦特（美国）
• 药明生物（中国）
• 三星生物製剂（韩国）
• IQVIA（美国）
• Syneos Health（美国）
• ICON Plc（爱尔兰）
• Medpace 控股公司（美国）
• 查尔斯河实验室（美国）
• PPD（美国）
• Labcorp 药物开发（美国）
• Parexel国际（美国）
• PRA 健康科学（美国）
• BioNTech SE (Germany)
• Moderna, Inc.（美国）
• 吉利德科学公司（美国）
• 再生元製药（美国）
• Vertex 製药公司（美国）
• 安进公司（美国）

结论和建议

Global Biopharmaceutical CMO & CRO Market size was valued at USD 32.4 billion in 2023 and is poised to grow from USD 34.31 billion in 2024 to USD 54.28 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The biopharmaceutical sector has seen rapid growth, now comprising over 20% of the global pharmaceutical market, largely driven by increasing consumer demand for therapeutic solutions. This expansion has been significantly influenced by the COVID-19 pandemic and rising investments aimed at enhancing productivity and efficiency within the industry. As biopharma companies focus on outsourcing resource-intensive processes, the reliance on Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) has surged, creating a lucrative demand for their services. Recent collaborations, such as the Australian government's investment with Sandoz in antibiotic manufacturing, further highlight the sector's commitment to innovative, integrated solutions. Mergers and acquisitions within this space enable CMOs to deliver comprehensive bioprocessing services, making them essential partners for expedited product development and market entry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceutical CMO & CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceutical CMO & CRO Market Segmental Analysis

Global Biopharmaceutical CMO and CRO Market is segmented by Source, Service Type, Product and region. Based on Source, the market is segmented into Mammalian and Non-mammalian. Based on Service Type, the market is segmented into Contract Manufacturing and Contract Research. Based on Product, the market is segmented into Biologics and Biosimilars. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceutical CMO & CRO Market

The global biopharmaceutical CMO and CRO market is poised for rapid growth due to the integration of innovative bioprocessing technologies and the adoption of single-use systems. Recently, the industry has experienced numerous consolidations aimed at enhancing competitiveness and operational efficiency. As new therapies and bioprocessing methods emerge, contract bioproducers face increasing pressure to adapt to shifting market demands. This has led to the development of alternative business models that cater to diverse stakeholder needs. Furthermore, the implementation of single-use technologies within manufacturing facilities is expected to significantly enhance production capabilities, thus creating new growth opportunities within the market throughout the forecast period.

Restraints in the Global Biopharmaceutical CMO & CRO Market

The Global Biopharmaceutical CMO and CRO market is currently facing significant restraints that hinder its growth, primarily due to high initial investments and limited outsourcing opportunities. Unlike the pharmaceutical CMO sector, which enjoys profit margins between 5% and 10%, the biopharmaceutical CMO market boasts margins exceeding 30%. However, the hefty investments required for advanced manufacturing facilities and cutting-edge equipment needed to accelerate biomanufacturing processes are impeding progress. Additionally, the reluctance of established biopharmaceutical companies to outsource further restricts market expansion. Complications arising from the regulatory environment and intricate contract negotiations, particularly concerning intellectual property rights, warranties, and confidentiality, exacerbate these challenges.

Market Trends of the Global Biopharmaceutical CMO & CRO Market

The Global Biopharmaceutical CMO & CRO market is witnessing a significant trend towards new product development, driven by increasing biopharmaceutical innovation and rising demand for specialized therapeutic solutions. As biopharma companies focus on accelerating drug discovery and reducing time-to-market, CMOs and CROs are enhancing their capabilities in advanced analytics, biologics production, and regulatory expertise. This trend is further fueled by collaborative partnerships and investments in technology, enabling companies to bring cutting-edge therapies, including personalized medicine and biologics, to fruition. Overall, the emphasis on new product development is expected to positively impact growth and competitiveness within the biopharmaceutical sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement

Global Biopharmaceutical CMO & CRO Market Size by Source & CAGR (2025-2032)

• Market Overview
• Mammalian
• Non-mammalian

Global Biopharmaceutical CMO & CRO Market Size by Service Type & CAGR (2025-2032)

• Market Overview
• Contract Manufacturing
  • Process Development
  • Downstream
  • Upstream
  • Fill & Finish Operations
  • Analytical & QC Studies
  • Packaging
• Contract Research
  • Oncology
  • Inflammation & Immunology
  • Cardiology
  • Neuroscience
  • Others

Global Biopharmaceutical CMO & CRO Market Size by Product & CAGR (2025-2032)

• Market Overview
• Biologics
  • Monoclonal antibodies (MAbs)
  • Recombinant Proteins
  • Vaccines
  • Antisense, RNAi, & Molecular Therapy
  • Others
• Biosimilars

Global Biopharmaceutical CMO & CRO Market Size & CAGR (2025-2032)

• North America (Source, Service Type, Product)
  • US
  • Canada
• Europe (Source, Service Type, Product)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Source, Service Type, Product)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Source, Service Type, Product)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Source, Service Type, Product)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Lonza Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace Holdings (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PRA Health Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations